173 related articles for article (PubMed ID: 37393265)
21. BRCA1 germline mutations may be associated with reduced ovarian reserve.
Wang ET; Pisarska MD; Bresee C; Chen YD; Lester J; Afshar Y; Alexander C; Karlan BY
Fertil Steril; 2014 Dec; 102(6):1723-8. PubMed ID: 25256924
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
Nañez A; Stram DA; Garcia C; Powell CB
Gynecol Oncol; 2021 Oct; 163(1):134-141. PubMed ID: 34330534
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
24. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
[TBL] [Abstract][Full Text] [Related]
25. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
[TBL] [Abstract][Full Text] [Related]
26. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
27. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
Hermsen BB; Olivier RI; Verheijen RH; van Beurden M; de Hullu JA; Massuger LF; Burger CW; Brekelmans CT; Mourits MJ; de Bock GH; Gaarenstroom KN; van Boven HH; Mooij TM; Rookus MA
Br J Cancer; 2007 May; 96(9):1335-42. PubMed ID: 17426707
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
Int J Gynecol Cancer; 2006; 16 Suppl 2():497. PubMed ID: 17010055
[TBL] [Abstract][Full Text] [Related]
29. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Bayraktar S; Jackson M; Gutierrez-Barrera AM; Liu D; Meric-Bernstam F; Brandt A; Woodson A; Litton J; Lu KH; Valero V; Arun BK
Breast J; 2015; 21(3):260-7. PubMed ID: 25789811
[TBL] [Abstract][Full Text] [Related]
30. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
31. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
32. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
33.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract][Full Text] [Related]
34. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
[TBL] [Abstract][Full Text] [Related]
35. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
[TBL] [Abstract][Full Text] [Related]
36. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract][Full Text] [Related]
39. The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.
Grandi G; Del Savio MC; Sammarini M; Cortesi L; Toss A; Piombino C; Facchinetti F
Eur J Cancer Prev; 2020 Jul; 29(4):350-356. PubMed ID: 32516171
[TBL] [Abstract][Full Text] [Related]
40. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
